Financial considerations in bispecific therapy are discussed.
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
Haumschild asks about unmet needs in operationalizing bispecific antibodies for hematologic malignancies. Chang shares her experience with bispecific coverage and reimbursement. While her organization has not encountered payer denials or unexpected prior authorizations, most bispecifics lack classified codes, delaying claim processing. Additional documentation like invoices may be requested. She emphasizes open communication with payers to facilitate approvals. Haumschild notes the importance of collaboration between providers and payers for timely access. Hanna describes how his pharmacy and therapeutics committee and clinical practice committee assessed bispecific operational considerations and clinical value. Quick adoption was justified by unprecedented response rates in highly refractory multiple myeloma. Similarly transformational impacts are expected across hematologic malignancies as familiarity increases. Haumschild concurs this is an exciting time, with many game-changing innovations emerging for lymphomas and myeloma. The discussion highlights the need to align operational logistics and payer policies with the clinical promise of bispecific therapies.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More